Twisted_Chemist
Bluelighter
- Joined
- Mar 23, 2018
- Messages
- 21
Wasnt sure if this went here or in advanced drug, move if wrong and I apologize.
I just got my prescription for truvada (emtricitabine/tenofovir disoproxil fumarate). I've searched around to try and figure it out, but truvada still does not have a interactions list that's complete. Any personal reaction would be greatly appreciated.
Mechanism of ActionEmtricitabine:
Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 reverse transcriptase (RT) by competing with the natural substratedeoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination. Emtricitabine 5′-triphosphate is a weak inhibitor of mammalian DNA polymerase α, β, ε and mitochondrial DNA polymerase γ.
Tenofovir disoproxil fumarate: Tenofovir disoproxil fumarate is an acyclic nucleosidephosphonate diester analog of adenosine monophosphate. Tenofovir disoproxil fumarate requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylationsby cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate inhibits the activityof HIV-1 RT by competing with the natural substrate deoxyadenosine 5′-triphosphate and,after incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weakinhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.
Pharmacokinetics
One TRUVADA Tablet was bioequivalent to one EMTRIVA Capsule (200 mg)plus one VIREAD Tablet (300 mg) following single-dose administration to fasting healthysubjects (N=39).
Emtricitabine: The pharmacokinetic properties of emtricitabine are summarized in Table 1.Following oral administration of EMTRIVA, emtricitabine is rapidly absorbed with peak plasma concentrations occurring at 1?2 hours post-dose. In vitro binding of emtricitabine to human plasma proteins is <4% and is independent of concentration over the range of 0.02−200 ?g/mL. Following administration of radio labelled emtricitabine, approximately 86%is recovered in the urine and 13% is recovered as metabolites. The metabolites of emtricitabine include 3′-sulfoxide diastereomers and their glucuronic acid conjugate. Emtricitabine is eliminated by a combination of glomerular filtration and active tubular secretion. Following a single oral dose of EMTRIVA, the plasma emtricitabine half-life is approximately 10 hours. Has No CYP interaction
Tenofovir disoproxil fumarate: The pharmacokinetic properties of tenofovir disoproxil fumarate are summarized in Table 1. Following oral administration of VIREAD, maximum tenofovir serum concentrations are achieved in 1.0 - 0.4 hour. In vitro binding of tenofovir to human plasma proteins is <0.7% and is independent of concentration over the range of 0.01?25 ?g/mL. Approximately 70?80% of the intravenous dose of tenofovir is recovered as unchanged drug in the urine. Tenofovir is eliminated by a combination of glomerular filtrationand active tubular secretion. Following a single oral dose of VIREAD, the terminal eliminationhalf-life of tenofovir is approximately 17 hours.
Tenofovir disoproxil is a prodrug that is quickly absorbed from the gut and cleaved to release tenofovir.[7] Inside cells, tenofovir is phosphorylated to tenofovir diphosphate (which is actually a triphosphate, as tenofovir itself already has one phosphate residue), the active compound that inhibits reverse transcriptase via chain termination.
In fasting persons, bioavailability is 25%, and highest blood plasma concentrations are reached after one hour.[13] When taken with fatty food, highest plasma concentrations are reached after two hours, and the area under the curve is increased by 40%.[13] It has no significant interactions with cytochrome P450 enzymes.
Tenofovir is mainly excreted via the kidneys, both by glomerular filtration and by tubular secretion using the transport proteins OAT1, OAT3 and ABCC4.
If you CL rate or anything from chart let me know. It is also in FDA Document NDA 21-752/S-005
From what I can tell their should not be any interactions, but better safe than sorry. And above an an abridged summery of the drugs, for full text see each individual drug. Only thing im worried about is the combo is boxing my kidneys or liver.
Thanks,
The Twisted Chemist
I just got my prescription for truvada (emtricitabine/tenofovir disoproxil fumarate). I've searched around to try and figure it out, but truvada still does not have a interactions list that's complete. Any personal reaction would be greatly appreciated.
Mechanism of ActionEmtricitabine:
Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 reverse transcriptase (RT) by competing with the natural substratedeoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination. Emtricitabine 5′-triphosphate is a weak inhibitor of mammalian DNA polymerase α, β, ε and mitochondrial DNA polymerase γ.
Tenofovir disoproxil fumarate: Tenofovir disoproxil fumarate is an acyclic nucleosidephosphonate diester analog of adenosine monophosphate. Tenofovir disoproxil fumarate requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylationsby cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate inhibits the activityof HIV-1 RT by competing with the natural substrate deoxyadenosine 5′-triphosphate and,after incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weakinhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.
Pharmacokinetics
One TRUVADA Tablet was bioequivalent to one EMTRIVA Capsule (200 mg)plus one VIREAD Tablet (300 mg) following single-dose administration to fasting healthysubjects (N=39).
Emtricitabine: The pharmacokinetic properties of emtricitabine are summarized in Table 1.Following oral administration of EMTRIVA, emtricitabine is rapidly absorbed with peak plasma concentrations occurring at 1?2 hours post-dose. In vitro binding of emtricitabine to human plasma proteins is <4% and is independent of concentration over the range of 0.02−200 ?g/mL. Following administration of radio labelled emtricitabine, approximately 86%is recovered in the urine and 13% is recovered as metabolites. The metabolites of emtricitabine include 3′-sulfoxide diastereomers and their glucuronic acid conjugate. Emtricitabine is eliminated by a combination of glomerular filtration and active tubular secretion. Following a single oral dose of EMTRIVA, the plasma emtricitabine half-life is approximately 10 hours. Has No CYP interaction
Tenofovir disoproxil fumarate: The pharmacokinetic properties of tenofovir disoproxil fumarate are summarized in Table 1. Following oral administration of VIREAD, maximum tenofovir serum concentrations are achieved in 1.0 - 0.4 hour. In vitro binding of tenofovir to human plasma proteins is <0.7% and is independent of concentration over the range of 0.01?25 ?g/mL. Approximately 70?80% of the intravenous dose of tenofovir is recovered as unchanged drug in the urine. Tenofovir is eliminated by a combination of glomerular filtrationand active tubular secretion. Following a single oral dose of VIREAD, the terminal eliminationhalf-life of tenofovir is approximately 17 hours.
Tenofovir disoproxil is a prodrug that is quickly absorbed from the gut and cleaved to release tenofovir.[7] Inside cells, tenofovir is phosphorylated to tenofovir diphosphate (which is actually a triphosphate, as tenofovir itself already has one phosphate residue), the active compound that inhibits reverse transcriptase via chain termination.
In fasting persons, bioavailability is 25%, and highest blood plasma concentrations are reached after one hour.[13] When taken with fatty food, highest plasma concentrations are reached after two hours, and the area under the curve is increased by 40%.[13] It has no significant interactions with cytochrome P450 enzymes.
Tenofovir is mainly excreted via the kidneys, both by glomerular filtration and by tubular secretion using the transport proteins OAT1, OAT3 and ABCC4.
If you CL rate or anything from chart let me know. It is also in FDA Document NDA 21-752/S-005
From what I can tell their should not be any interactions, but better safe than sorry. And above an an abridged summery of the drugs, for full text see each individual drug. Only thing im worried about is the combo is boxing my kidneys or liver.
Thanks,
The Twisted Chemist
Last edited: